August 2^nd 2016, Tianjin CanSino submits the Clinical trial application for the component DTP combo vaccine and successfully receives the “drug application registration”. This product is the first DTP vaccine for adults and teenagers in China. Epidemic investigation data shows that adults and teenagers are a group susceptible to high exposure and transmission. Many developed countries have amended the Expanded Program on Immunizations (EPI) to strengthen the 

immunization of adults and teenagers with the DTP vaccine. However, the current EPI in China only covers vaccination with DTP for infants, excluding adults and teenagers. CanSino’s DTP vaccine is based on a genetically modified pertussis strain and state of the art fermentation and purification processes are able to overcome the current purification defects present in marketed 

products. Current defects include the fact that the antigen cannot be quantified which leads to huge differences between batches and a high percentage of adverse effects. The safety and immunogenicity of this product was approved in preclinical studies and the quality is well controlled.